Trial Profile
Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 03 Aug 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Primary endpoint (Percentage change of serum unconjugated estradiol concentration) has not been met according to the results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology